Physician profile
James Forest Call
NPI 1033759774
$3,869.63
in general payments reported to CMS, 2019-2025
26 companies · $1,350 in 2025
The $1,350 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,632 · 2024: $887 · 2025: $1,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,287 · Travel and Lodging: $564 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,287.31 |
| Travel and Lodging | $564.32 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $998.41 | 2023-2025 | Urolift, Barrigel |
| Sumitomo Pharma America, INC. | $621.56 | 2023-2025 | Orgovyx, Gemtesa |
| Dendreon Pharmaceuticals LLC | $329.92 | 2023-2025 | Provenge |
| Janssen Biotech, INC. | $204.86 | 2024-2025 | Erleada |
| Boston Scientific Corporation | $194.21 | 2025 | Lumenis Pulse 120h, Axonics |
| Bayer Healthcare Pharmaceuticals INC. | $177.24 | 2023-2025 | |
| Medtronic, INC. | $166.48 | 2023-2025 | Interstim |
| Merck Sharp & Dohme LLC | $158.52 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Axonics, INC. | $142.14 | 2023-2024 | Axonics, Bulkamid |
| Endo USA, INC. | $119.29 | 2024-2025 | Xiaflex |
| Procept Biorobotics Corporation | $105.53 | 2023 | Aquabeam Robotic System |
| Myriad Genetic Laboratories, INC. | $89.85 | 2023-2024 | Prolaris |
| Urogen Pharma, INC. | $88.18 | 2024-2025 | |
| Astellas Pharma US INC | $78.37 | 2025 | Xtandi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.24 | 2025 | Caplyta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $34.74 | 2024-2025 | Adstiladrin |
| Pfizer INC. | $34.67 | 2024-2025 | |
| Antares Pharma, INC. | $31.90 | 2023 | Tlando, Nocdurna, Xyosted |
| Halozyme INC | $31.67 | 2023 | |
| Abbvie INC. | $30.62 | 2024 | |
| Tolmar, INC. | $30.37 | 2023-2025 | Jatenzo, Eligard |
| Astrazeneca Pharmaceuticals LP | $27.10 | 2023 | Lynparza |
| Immunitybio, INC. | $25.38 | 2025 | |
| 180 Medical, INC. | $25.29 | 2023 | Gentlecath |
| Novartis Pharmaceuticals Corporation | $23.53 | 2025 | |
| Progenics Pharmaceuticals, INC. | $21.56 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Call listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.